ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Camus, Ph.
Right arrow Articles by Ask, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camus, Ph.
Right arrow Articles by Ask, K.
Eur Respir J 2001; 18:93S-100S
Copyright ©ERS Journals Ltd 2001


Drug-induced infiltrative lung disease

Ph. Camus, P. Foucher, Ph. Bonniaud and K. Ask

Service de Pneumologie et de Réanimation Respiratoire, Centre Hospitalier Universitaire de Dijon, et Unité de Pharmacologie Toxicologie Pulmonaire, Université de Bourgogne, Dijon, France

CORRESPONDENCE: Ph. Camus, Service de Pneumologie et de Réanimation Respiratoire, CHU de Dijon, Dijon, France. Fax: 33 380293251

Keywords: drug-induced lung disease, drugs, lung toxicity, patients, registry, web technology

Received: March 8, 2001
An increasing number of drugs are recognized to induce distinctive patterns of infiltrative lung disease (ILD), ranging from benign infiltrates to life-threatening adult respiratory distress syndromes. In addition to drugs, biomolecules such as proteins and cytokines, and medicinal plants are also capable of inducing respiratory disease, some being severe and/or irreversible.

For several reasons it is difficult to estimate the exact frequency of drug-induced infiltrative lung disease (DI-ILD). The risk for DI-ILD and the clinical patterns vary depending on a variety of host and drug factors.

Although establishing the diagnosis is often difficult, systematic evaluation of the possible role of almost any kind of drugs in ILD is warranted, as stopping a drug may favourably influence prognosis. However, prognosis depends on the drug and the type of DI-ILD. Corticosteroids may suppress the inflammatory reaction, but for many drugs, proof of the effect of corticosteroids is lacking.

Advances in prevention and prediction are needed. A user-friendly database of respiratory adverse drug reactions was made available on the web, to provide quick information in this area.




This article has been cited by other articles:


Home page
BMJHome page
C. Terzano and A. Petroianni
Clarithromycin and pulmonary infiltration with eosinophilia
BMJ, June 19, 2003; 326(7403): 1377 - 1378.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the European Respiratory Society.